Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D Global Biotech (ROCO:6808) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
3D Global Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,169.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Global Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$21.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3D Global Biotech EV-to-EBIT Related Terms
3D Global Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for 3D Global Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6808 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, 3D Global Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Global Biotech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Global Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where 3D Global Biotech's EV-to-EBIT falls into.
3D Global Biotech's current Enterprise Value is NT$1,884.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Global Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$21.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3D Global Biotech (ROCO:6808) has a EV-to-EBIT of 89.32 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on 3D Global Biotech and its competitors. According to the industry distribution chart, 3D Global Biotech ranks #340 out of 369 companies in the Biotechnology industry, placing it in the top 92.1%.
Is 3D Global Biotech's EV-to-EBIT too high?
3D Global Biotech's current EV-to-EBIT is 89.32. The Biotechnology industry median EV-to-EBIT is 14.64. 3D Global Biotech's value of 89.32 is 510.1% above this industry median. Based on the distribution chart, 3D Global Biotech ranks #340 out of 369 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 3D Global Biotech has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Global Biotech's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Global Biotech ranks #340 out of 369 companies for EV-to-EBIT. This places 3D Global Biotech in the lower half of its industry. The industry median EV-to-EBIT is 14.64. 3D Global Biotech's value of 89.32 is 510.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.64, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3D Global Biotech's current EV-to-EBIT of 89.32 is 510.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on 3D Global Biotech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3D Global Biotech's current EV-to-EBIT is 89.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Global Biotech stock overvalued right now?
Based on GuruFocus' analysis, 3D Global Biotech (ROCO:6808) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$37.21, compared to a current price of NT$30.35 — trading 18.4% below its estimated fair value. The current EV-to-EBIT is 89.32 and 510.1% above the Biotechnology industry median of 14.64. 3D Global Biotech's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For 3D Global Biotech (ROCO:6808), the current EV-to-EBIT is 89.32 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Global Biotech (ROCO:6808) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Global Biotech stock appears to be undervalued.
The current stock price of NT$30.35 is trading 18.4% below its estimated GF Value™ of NT$37.21.
GuruFocus considers 3D Global Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6808:
EV-to-EBIT: 89.32
GF Value™: NT$37.21 vs. price of NT$30.35 (18.4% below fair value)
Industry Position: 510.1% above the Biotechnology median (#340 of 369)
No single metric tells the full story. See the ROCO:6808 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Global Biotech Inc is engaged in the research and development of high-end medical equipment and biological 3D printing technology and the sale of medical Materials and other related products.
81GF Score
Get the complete analysis for ROCO:6808
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6808 has been successfully added to your 
